Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to greater than or equal to 2 NSAIDs.

Next Previous
Trial Profile

Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to greater than or equal to 2 NSAIDs.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use

Most Recent Events

  • 19 Dec 2013 Status changed from recruiting to completed.
  • 30 Oct 2013 Parent and extension study results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 01 Jun 2011 Planned end date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top